HTA44 Reimbursement Outcomes for EMA Conditionally Authorized Orphan Drugs (2022-2023): Implications for Joint Clinical Assessment Requirements
Abstract
Authors
Andrea Liborio Monteiro Florian Csintalan Michael Epstein Susanne S. Michel